Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525007 | 0.83 | THRB (0.43) | RAB9ANPC1LMNASMN1; SMN2KDM4E | |
| SCHEMBL14844945 | 0.83 | NISCH (0.38) | RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL2522518 | 0.83 | GRM5 (0.51) | ALDH1A1 | |
| SCHEMBL14844863 | 0.81 | THRB (0.45) | RAB9AKDM4EALDH1A1 | |
| SCHEMBL2523357 | 0.79 | KDM4E (0.41) | LMNAHTTKDM4EMAPT | |
| SCHEMBL2524414 | 0.78 | GRM5 (0.50) | — | |
| SCHEMBL2524849 | 0.78 | KDM4E (0.42) | LMNAHTTKDM4EALDH1A1MAPT | |
| SCHEMBL2527289 | 0.73 | CHRNB4 (0.42) | LMNAHTTKDM4EALDH1A1HPGD | |
| SCHEMBL16843692 | 0.72 | — | — | |
| SCHEMBL2524483 | 0.70 | HRH4 (0.39) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947303-B | Bicyclo-pyridyl pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-12-14 | — | — | CN | disclosed |
| EP-2556073-B1 | BICYCLIC PYRIDINYL PYRAZOLES | BAYER IP GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8507472-B2 | Bicyclic pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-13 | — | — | US | disclosed |
| CN-102947303-A | Bicyclic pyrimidinyl pyrazoles | BAYER CROPSCIENCE AG | 2013-02-27 | — | — | CN | disclosed |
| EP-2556073-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124539-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | RAB9A 3773/4885NPC1 4033/4885LMNA 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.